Search PubMed⌕ Search

Biomedical subjects

J Fleischer

Publications and source records attributed to J Fleischer.

At least 73 records · Page 4Linked to original sources
PubMed1981

[The blood coagulation system in liver diseases with special reference to liver transplantation].

The central function of the liver as place of the formation of the most plasmatic coagulation factors in expressed by coagulation disturbances in severe liver diseases. Apart for intoxications, vitamin-K-deficiency and relatively rare congenital dysproteinoses the synthesis of the coagulation factors is apparently a relatively stable and rapidly recoverable function of the hepatocyte. On the other hand, however, the pathogenetic dominance of the accelerated balance in the sense of a disseminated intravasal coagulation and a secondarily increased fibrinolysis is emphasized for the severe disturbances of haemostasis in hepatopathies. In all kinds of shock, in tumours, inflammations, sepsis and intoxications as well as in portal hypertension of any reason the activation of the coagulation system up to the consumption coagulopathy develops. In the liver transplantation in addition to the operation shock deterioratingly comes the intensive blood contact with the often heavily damaged graft cells, the effectors of the immune system (rejection), the temporary disturbance of the clearance function of the liver RES and the basic disease of the recipient which in most cases disposes to the disseminated intravasal coagulation. The reduction of thrombocytes and coagulation factors extensively transgresses the changes which are to be expected by a weakness of the synthesis during and immediately after the anhepatic phase. For the therapy the demand of rapid removal of the coagulation-activating moments (minimum times of ischaemia, careful anastomoses) and of an adequate substitution with simultaneous prevention of the disseminated intravasal coagulation by heparinisation.

Blood Coagulation Factors↗
PubMed1980

[Course of pulmonary involvement in patients with Hodgkin's disease].

65 patients with Hodgkin's disease and pulmonary involvement were observed during the fifteen years from 1964 to 1978. Polychemotherapy was administered to 24 patients and monochemotherapy to 28. Six of the 24 patients on polychemotherapy reached the four-year limit after diagnosis of pulmonary involvement. The results in the patients on monochemotherapy were significantly worse. None of the male patients lived longer than 28 months. None of the patients with mixed cellularity and lymphocyte depleted histology had a survival of more than one year after diagnosis of the pulmonary involvement.

Antineoplastic Agents↗
PubMed1980

[Significance of pathological diagnosis for treatment of patients with lymphogranulomatosis and for prognosis (author's transl)].

The survey begins with some pathophysiological considerations which concern the elicitation of the Morbus Hodgkin being defined by immunological reactions. The clinical signs of the four histological subtypes are followed by the importance of the stage diagnosis for therapy and survival time. The presence of general symptoms affects the survival time too like the kind of organ manifestation in stage IV. In the chapter dealing with the therapy the enlarging part of the chemotherapy besides the radiotherapy can be seen. The ingenious combination caused prolongation of the survival time already.

Hodgkin Disease↗
PubMed1979

[Therapy of non-Hodgkin lymphomas].

The survey is introduced by references to the relations between special diagnostic findings and life expectancy. Also the contribution of the clinician to the diagnostics of the non-Hodgkin-lymphomas is dealt with. Five standpoints are to be regarded in the new management of chemotherapy: 1. The polychemotherapy is more effective than the monotherapy. 2. Massive-dose therapies of middle degree are more favourable than frequent, low-dosed cytostatic dosages. 3. Connection of the polychemotherapy with the radiotherapy in stage III and IV. 4. Particularly in the lymphomas with a high degree of malignancy polychemotherapy already in stage II following the radiation. 5. Especially intensive polychemotherapy in the lymphomas with a high degree of malignancy. The hitherto got findings in the polychemotherapy of the non-Hodgkin-lymphomas are reported. Here particularly the COP-scheme proved to be favourable, if necessary in connection with bleomycin, adriamycin or methotrexat; also BCNU or dakarbacin are possible. Own propositions, separated for lymphomas for low and high malignancy, respectively, take into consideration also the GDR-preparation Cytostasan.

Bleomycin↗
PubMed1979

[Splenectomy and polychemotherapy in chronic myelosis].

It is referred to the possibility of the splenectomy in the early phase of the chronic myelosis in the time of the first remission. The intervention cannot be recommended generally and should be used only now and then in centres which have rooms at their disposal which are poor in germs. Own experiences speak for the fact to extend the polychemotherapy of the blast crisis of the chronic myelosis to its prephase, when an increasing therapy resistance occurs, the spleen becomes clearly larger, the number of blasts in the bone-marrow increases and single blasts may be proved in the peripheral blood. Combinations of two or three medicaments, such as Busulfan, Myelobromol, Merkaleukin, Methotrexat, Hydroxyurea, Alexan, Vinkristin or Rubomycin seem to be favourable.

Busulfan↗